Scientists developed the first migraine treatments in the late 1920s. Today, numerous treatments exist to both prevent and treat migraine attacks.
The first known mention of migraine was in 1550 B.C.E., when it appeared in ancient Egyptian medical documents.
Since then, doctors have sought to treat and prevent the pain and other symptoms associated with migraine.
Keep reading to learn more about the history of migraine treatment from the late 1920s to the present day.
In the 1920s, the first medication for migraine became available.
Ergotamine was the first drug that doctors used in the treatment of acute migraine. Even though its release was back in 1926, it remains popular because it is a low cost drug that remains effective for a long time.
People use ergotamine to treat long lasting migraine attacks that typically involve headache recurrence.
The drug comes in different formulations, including:
- oral pill
- suppository, usually containing caffeine
- IV infusion
Ergotamine works by increasing serotonin levels and reducing inflammation. However, it also constricts blood vessels, so it is not suitable for people with certain conditions, such as uncontrolled hypertension. It also frequently causes significant adverse effects and carries a high risk of dependence.
This period saw the introduction of beta-blockers to migraine treatment.
In 1966, Dr. Robert Rabkin was researching the effects of a beta-blocker called propranolol on heart pain. During his research, he noticed that one of his study participants experienced a significant reduction in the frequency of migraine attacks.
A decade later, two other doctors presented their findings on using propranolol daily for the treatment of migraine to the Food and Drug Administration (FDA). The FDA then approved propranolol as the first medication for the prevention of migraine attacks.
Propranolol is now among a group of beta-blockers, including timolol and metoprolol, that people can use to prevent migraine attacks. It is one of the preventive migraine medications that doctors around the world most commonly prescribe.
Beta-blockers slow the heart rate, relax blood vessels, and improve blood flow throughout the body. However, experts are not entirely sure how their effects help treat migraine.
The medical community regards beta-blockers as one of the most significant medical discoveries of the 20th century. This is because as well as playing a role in migraine care, they can also help treat:
- high blood pressure
- certain types of tremors
- chest pain
- irregular heartbeat
During this period, more effective medications became available to people with migraine.
Doctors considered the development of triptans to be
The first triptan, called sumatriptan, became available in 1991 in Europe. Until that time, no other drug had proven to be as effective in treating migraine.
In 2008, the American Headache Society declared that triptans were the most important breakthrough in headache medicine in 50 years.
Drugs in this class prevent pain signals from reaching the brain. They also block the release of substances that cause pain and other symptoms of migraine, such as nausea.
For decades, experts believed that migraine attacks were the result of a problem with blood vessels in the brain.
However, from the late 80s to the early 2000s, researchers worked to prove that dysfunctional nerve signals also played a role.
According to a research article in Cephalalgia, the journal of the International Headache Society, researchers thought that the nerves that transmit pain sensations between the face and brain — the trigeminal nerves — and a signaling molecule called calcitonin gene-related peptide (CGRP) played a crucial role in migraine.
CGRP is a type of protein present in the nervous system and brain. It plays a role in pain transmission in the body. The release of CGRP in the body can lead to pain from inflammation in the meninges, the protective membrane layers that surround the brain.
Researchers published the first proof-of-concept study of IV anti-CGRP therapy in 2004. This work paved the way for the development of different types of migraine drugs, including CGRP antibodies and CGRP gepants, in later decades.
A range of new treatment options became available during this time.
The approval was based on research that found Botox to be effective in reducing both the severity and frequency of headaches in those with chronic migraine. The treatment was also well-tolerated.
Cerena TMS device
In 2013, the FDA approved the first device for the treatment of migraine symptoms. The manufacturers designed the device for use at home.
The device, which is called the Cerena Transcranial Magnetic Stimulator (TMS), works by delivering short pulses of magnetic energy to the back of the head. This, in turn, causes an electrical current in a certain part of the brain called the occipital cortex. This current can help reduce or eliminate the effects of migraine with aura.
Since the Cerena TMS approval, the FDA has approved several other therapeutic devices, which are generally smaller and less expensive. The approved models are:
CGRP monoclonal antibodies work by removing excess CGRP molecules. By blocking the release of this naturally occurring substance into the body, the treatment reduces or stops migraine attacks.
The first of these drugs, erenumab-aooe (Aimovig), received FDA approval
It was the first approved preventive migraine treatment that blocks the activity of the CGRP molecule. Today, doctors may also prescribe other CGRP antibody medications, such as galcanezumab (Emgality).
Ditans are also called selective serotonin receptor agonists.
In 2019, the FDA approved the first of these drugs: lasmiditan (Reyvow). It was the first new class of acute migraine treatment to receive approval in more than 20 years.
Reyvow works by stopping the inflammation of nerves and preventing pain signals from traveling to the brain.
People need to take this medication at the first sign of a migraine attack.
CGRP gepants are a type of CGRP receptor antagonist. This means that they stop the CGPR molecule from properly binding to receptor sites in the body. In doing so, they can stop the chain of events that results in a migraine attack.
Unlike triptan medications, gepants do not cause blood vessels to constrict, so they are safe for people with heart or vascular disease and those who have had a stroke.
CGRP antibody IV infusion
The first preventive IV migraine treatment, eptinezumab-jjmr (Vyepti), received FDA approval in 2020.
The drug works by blocking CGRP in the brain, which stops pain signals.
Healthcare professionals deliver it via an IV infusion over a 30-minute period, typically once every 3 months. In two phase 3 clinical trials — PROMISE-1 for episodic migraine and PROMISE-2 for chronic migraine — it significantly reduced the number of headache days per month.
Over time, migraine treatments evolved from the use of beta-blockers in the 1960s to the development of triptans in the early 90s. The medical community considered the development of triptans as a medical breakthrough in the field of migraine care.
Since then, researchers have developed other treatments, including Botox and therapeutic stimulation devices.
Once CGRP became a proven target for migraine treatment and prevention in the early 2000s, CGRP therapies revolutionized the field of migraine care.